Annals of Emergency Medicine
Volume 50, Issue 3 , Pages 280-281, September 2007

Patient-Tailored Acetylcysteine Administration

  • Richard C. Dart, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Richard C. Dart, MD, PhD, Rocky Mountain Poison and Drug Center, 777 Bannock Street, Mail Code 0180, Denver, CO 80204; 303-739-1240, fax 303-739-1443.
    • ,
  • Barry H. Rumack, MD

Rocky Mountain Poison and Drug Center, Denver Health and Hospitals, and the University of Colorado Health Sciences Center, Denver, CO.

published online 06 April 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supervising editor: Michael L. Callaham, MD

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that may create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Dr. Dart has received research funding and acted as a consultant for McNeil Consumer Products, the manufacturer of Tylenol. By the policy of Denver Health and Hospitals, all revenue is retained by Denver Health and Hospitals. Dr. Dart receives no salary, bonuses, or incentives that are directly or indirectly related to fees paid to Denver Health by McNeil Consumer Products. Dr. Rumack has acted as an expert witness on issues involving acetaminophen toxicity on behalf of McNeil Consumer Products, the manufacturer of Tylenol.

 Publication dates: Available online April 5, 2007.

 Reprints not available from the authors.

PII: S0196-0644(07)00075-3

doi:10.1016/j.annemergmed.2007.01.015

Refers to article:

  • A Prospective Evaluation of Shortened Course Oral N-Acetylcysteine for the Treatment of Acute Acetaminophen Poisoning , 08 January 2007

    David P. Betten, F. Lee Cantrell, Stephen C. Thomas, Saralyn R. Williams, Richard F. Clark
    Annals of Emergency Medicine September 2007 (Vol. 50, Issue 3, Pages 272-279)

Annals of Emergency Medicine
Volume 50, Issue 3 , Pages 280-281, September 2007

Article Tools